Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Jul 31;25(1):515.
doi: 10.1186/s13063-024-08354-9.

Effect of nano-curcumin supplementation on cardiometabolic risk factors, physical and psychological quality of life, and depression in patients with coronary slow flow phenomenon: a randomized double-blind clinical trial

Mitra Soltani  1 , Mohammad Javad Hosseinzadeh-Attar  2   3 , Mahsa Rezaei  1 , Elham Alipoor  1   4 , Ali Vasheghani-Farahani  5   4 , Mehdi Yaseri  6 , Seyed Mahdi Rezayat  7   8
Affiliations
Randomized Controlled Trial

Effect of nano-curcumin supplementation on cardiometabolic risk factors, physical and psychological quality of life, and depression in patients with coronary slow flow phenomenon: a randomized double-blind clinical trial

Mitra Soltani et al. Trials. .

Abstract

Background: Extensive evidence has suggested the cardio-protective properties of the polyphenol curcumin. The aim of this study was to investigate the effects of a highly bioavailable curcumin supplement on cardiometabolic risk factors, health-related quality of life, and depression in patients with coronary slow flow phenomenon (CSFP).

Methods: This randomized double-blind placebo-controlled clinical trial was conducted in 42 patients with CSFP (age 35-70 years, 25 ≤ body mass index < 40 kg/m2). Patients received either 80 mg/day nano-curcumin or placebo for 12 weeks. Serum levels of visfatin, high-sensitivity C-reactive protein (hs-CRP), and glycemic indices were measured before and after the intervention. The short form 36-item quality of life (SF-36) and Beck's Depression Inventory-II (BDI-II) questionnaires were assessed, as well.

Results: No significant improvements were observed in circulating hs-CRP and visfatin following the intervention. A significant increase was observed in pre- to post-fasting blood glucose (- 0.9 ± 12.2 vs. 7.7 ± 12.4 mg/dl, p = 0.02) and hemoglobin A1C (- 0.1 ± 0.8 vs. 0.5 ± 0.8%, p = 0.04) levels, in the placebo compared with the intervention group. Physical (8.2 ± 8.1 vs. - 1.2 ± 6.5, p < 0.001) and mental (6.8 ± 11.8 vs. - 1.1 ± 10.4, p = 0.02) component summary scores were significantly improved in the nano-curcumin than the placebo group. Additionally, the number of patients with lower degrees of depression was significantly better in the intervention than the placebo group following the supplementation (p = 0.046).

Conclusion: Curcumin supplementation prevented deterioration of glycemic control and improved physical and psychological quality of life and depression in patients with CSFP.

Trial registration: Iranian Registry of Clinical Trials (IRCT20131125015536N8), June 19, 2019.

Keywords: Cardiometabolic risk factors, Quality of life; Coronary slow flow phenomenon; Curcumin; Depression; Glycemic control.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
CONSORT flow chart
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Tambe A, Demany M, Zimmerman HA, Mascarenhas E. Angina pectoris and slow flow velocity of dye in coronary arteries—a new angiographic finding. Am Heart J. 1972;84(1):66–71. 10.1016/0002-8703(72)90307-9 - DOI - PubMed
    1. Wang X, Nie S-P. The coronary slow flow phenomenon: characteristics, mechanisms and implications. Cardiovasc Diagnos Ther. 2011;1(1):37. - PMC - PubMed
    1. Mangieri E, Macchiarelli G, Ciavolella M, Barillà F, Avella A, Martinotti A, Dell’Italia LJ, Scibilia G, Motta P, Campa PP. Slow coronary flow: clinical and histopathological features in patients with otherwise normal epicardial coronary arteries. Cathet Cardiovasc Diagn. 1996;37(4):375–81. 10.1002/(SICI)1097-0304(199604)37:4<375::AID-CCD7>3.0.CO;2-8 - DOI - PubMed
    1. Beltrame J, Ganz P: The coronary slow flow phenomenon. In: Chest pain with normal coronary arteries. edn. Springer; 2013: 101–117.
    1. Beltrame JF, Limaye SB, Wuttke RD, Horowitz JD. Coronary hemodynamic and metabolic studies of the coronary slow flow phenomenon. Am Heart J. 2003;146(1):84–90. 10.1016/S0002-8703(03)00124-8 - DOI - PubMed

Publication types

MeSH terms